127 related articles for article (PubMed ID: 38603866)
41. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.
Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM
Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204
[TBL] [Abstract][Full Text] [Related]
42. The prognostic value of KRAS and BRAF in stage I-III colorectal cancer. A systematic review.
Gallo G; Sena G; Vescio G; Papandrea M; Sacco R; Trompetto M; Sammarco G
Ann Ital Chir; 2019; 90():127-137. PubMed ID: 30739887
[TBL] [Abstract][Full Text] [Related]
43. Double
Deshwar A; Margonis GA; Andreatos N; Barbon C; Wang J; Buettner S; Wagner D; Sasaki K; Beer A; Løes IM; Pikoulis E; Damaskos C; Garmpis N; Kamphues K; He J; Kaczirek K; Poultsides G; Lønning PE; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
Anticancer Res; 2018 May; 38(5):2891-2895. PubMed ID: 29715113
[TBL] [Abstract][Full Text] [Related]
44. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
45. The primary tumor location impacts survival outcome of colorectal liver metastases after hepatic resection: A systematic review and meta-analysis.
Liu W; Wang HW; Wang K; Xing BC
Eur J Surg Oncol; 2019 Aug; 45(8):1349-1356. PubMed ID: 31054852
[TBL] [Abstract][Full Text] [Related]
46. Prognostic Role of BRAF Mutation in Stage II/III Colorectal Cancer Receiving Curative Resection and Adjuvant Chemotherapy: A Meta-Analysis Based on Randomized Clinical Trials.
Zhu L; Dong C; Cao Y; Fang X; Zhong C; Li D; Yuan Y
PLoS One; 2016; 11(5):e0154795. PubMed ID: 27138801
[TBL] [Abstract][Full Text] [Related]
47. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.
Okuno M; Goumard C; Kopetz S; Vega EA; Joechle K; Mizuno T; Omichi K; Tzeng CD; Chun YS; Vauthey JN; Conrad C
Ann Surg Oncol; 2018 Aug; 25(8):2457-2466. PubMed ID: 29786130
[TBL] [Abstract][Full Text] [Related]
48. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection.
Passot G; Denbo JW; Yamashita S; Kopetz SE; Chun YS; Maru D; Overman MJ; Brudvik KW; Conrad C; Aloia TA; Vauthey JN
Surgery; 2017 Feb; 161(2):332-340. PubMed ID: 27592215
[TBL] [Abstract][Full Text] [Related]
49. Resectability and resection rates of colorectal liver metastases according to RAS and BRAF mutational status: prospective study.
Uutela A; Nordin A; Osterlund E; Halonen P; Kallio R; Soveri LM; Salminen T; Ålgars A; Ristimäki A; Ovissi A; Lamminmäki A; Muhonen T; Kononen J; Ristamäki R; Heervä E; Stedt H; Lehtomäki K; Kytölä S; Sundström J; Mäkinen MJ; Nieminen L; Kuopio T; Keinänen M; Osterlund P; Isoniemi H;
Br J Surg; 2023 Jul; 110(8):931-935. PubMed ID: 36511370
[No Abstract] [Full Text] [Related]
50. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract][Full Text] [Related]
51. Introduction of the resection severity index as independent risk factor limiting survival after resection of colorectal liver metastases.
Gwiasda J; Schrem H; Kaltenborn A; Mahlmann J; Mix H; Lehner F; Kayser N; Klempnauer J; Kulik U
Surg Oncol; 2017 Dec; 26(4):382-388. PubMed ID: 29113656
[TBL] [Abstract][Full Text] [Related]
52. Reevaluating the prognostic value of RAS mutation status in patients with resected liver metastases from colorectal cancer: A systematic review and meta-analysis.
Pikoulis E; Papaconstantinou D; Pikouli A; Wang J; Theodoridis C; Margonis GA
J Hepatobiliary Pancreat Sci; 2021 Aug; 28(8):637-647. PubMed ID: 34115442
[TBL] [Abstract][Full Text] [Related]
53. Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status.
Kawaguchi Y; Kopetz S; Tran Cao HS; Panettieri E; De Bellis M; Nishioka Y; Hwang H; Wang X; Tzeng CD; Chun YS; Aloia TA; Hasegawa K; Guglielmi A; Giuliante F; Vauthey JN
Br J Surg; 2021 Aug; 108(8):968-975. PubMed ID: 33829254
[TBL] [Abstract][Full Text] [Related]
54. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis.
Wu M; Kim YS; Ryu HS; Choi SC; Kim KY; Park WC; Kim MS; Myung JY; Choi HS; Kim EJ; Lee MY
Pathol Res Pract; 2020 Jan; 216(1):152791. PubMed ID: 31866097
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients.
Margonis GA; Buettner S; Andreatos N; Wagner D; Sasaki K; Barbon C; Beer A; Kamphues C; Løes IM; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
Ann Surg; 2019 Jun; 269(6):1129-1137. PubMed ID: 31082912
[TBL] [Abstract][Full Text] [Related]
56. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.
Nash GM; Gimbel M; Shia J; Nathanson DR; Ndubuisi MI; Zeng ZS; Kemeny N; Paty PB
Ann Surg Oncol; 2010 Feb; 17(2):572-8. PubMed ID: 19727962
[TBL] [Abstract][Full Text] [Related]
57. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer.
Morris V; Overman MJ; Jiang ZQ; Garrett C; Agarwal S; Eng C; Kee B; Fogelman D; Dasari A; Wolff R; Maru D; Kopetz S
Clin Colorectal Cancer; 2014 Sep; 13(3):164-71. PubMed ID: 25069797
[TBL] [Abstract][Full Text] [Related]
58. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
[TBL] [Abstract][Full Text] [Related]
59. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.
Atreya CE; Sangale Z; Xu N; Matli MR; Tikishvili E; Welbourn W; Stone S; Shokat KM; Warren RS
Cancer Med; 2013 Aug; 2(4):496-506. PubMed ID: 24156022
[TBL] [Abstract][Full Text] [Related]
60. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
